The relationship of clinical factors and radiation exposure rates from iodine-131 treated thyroid carcinoma patients
Journal Article
·
· Medical Dosimetry; (USA)
OSTI ID:5958072
- Washington Univ. School of Medicine, St. Louis, MO (USA)
Iodine-131 (I-131) was administered orally 58 times over a 31-month period to patients with thyroid carcinoma. Federal regulations (10 CFR 35) require that a patient remain hospitalized until total body activity is less than 30 mCi. This mandated a hospitalization of more than 48 hours in 10 of 58 patients (17%), and greater than 72 hours in 1 of 58 patients (2%). During each administration of I-131 exposure rates were periodically measured throughout the hospitalization at the surface of the neck, 1 meter from the neck surface, the surface of the abdomen, 1 meter from the anterior abdominal surface, and 1 meter from the lateral abdominal surface. Semi-log regression curves were generated for exposure rate versus time for various parameters, including tumor histology, extent of surgery, gender, age, TSH, site of measurement, and administered activity. The endpoint evaluated was the regressed time to reduce the exposure rate to 10% of the initial value. None of the clinical characteristics tested revealed any differences in decay times. The measurements taken 1 meter anterior to the stomach and neck surface were found to correlate best with decay time. We conclude that exposure rate assessments for the purpose of hospital discharge should be made at 1 meter anterior to the stomach or neck, and that individual patient measurements are necessary because none of the clinical parameters were predictive of I-131 elimination.
- OSTI ID:
- 5958072
- Journal Information:
- Medical Dosimetry; (USA), Journal Name: Medical Dosimetry; (USA) Vol. 15:4; ISSN 0739-0211; ISSN MEDOE
- Country of Publication:
- United States
- Language:
- English
Similar Records
Maximal radiation therapy by a new treatment technique for stage III ovarian cancer. [Intra-abdominal /sup 32/P and abdominal and pelvic external /sup 60/C]
Distribution of abdominal and pelvic Hodgkin disease: implications for CT scanning
EXPERIMENTAL STUDIES ON THE ELIMINATION OF RADIOIODINE FROM THE BODY
Journal Article
·
Sat Dec 31 23:00:00 EST 1977
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:6754703
Distribution of abdominal and pelvic Hodgkin disease: implications for CT scanning
Journal Article
·
Wed May 01 00:00:00 EDT 1985
· J. Comput. Assist. Tomogr.; (United States)
·
OSTI ID:5021525
EXPERIMENTAL STUDIES ON THE ELIMINATION OF RADIOIODINE FROM THE BODY
Journal Article
·
Sat Nov 30 23:00:00 EST 1963
· Health Physics (England)
·
OSTI ID:4103474
Related Subjects
550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL HALF-LIFE
BODY
CARCINOMAS
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
ENDOCRINE GLANDS
GLANDS
INTERMEDIATE MASS NUCLEI
IODINE 131
IODINE ISOTOPES
ISOTOPES
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANS
PATIENTS
RADIATION DOSES
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
THERAPY
THYROID
WHOLE-BODY COUNTING
62 RADIOLOGY AND NUCLEAR MEDICINE
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL HALF-LIFE
BODY
CARCINOMAS
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
ENDOCRINE GLANDS
GLANDS
INTERMEDIATE MASS NUCLEI
IODINE 131
IODINE ISOTOPES
ISOTOPES
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANS
PATIENTS
RADIATION DOSES
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
THERAPY
THYROID
WHOLE-BODY COUNTING